Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) Return on Invested Capital (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Return on Invested Capital for 12 consecutive years, with 0.75% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Invested Capital rose 15.0% year-over-year to 0.75%, compared with a TTM value of 0.75% through Dec 2025, up 15.0%, and an annual FY2025 reading of 0.86%, down 17.0% over the prior year.
  • Return on Invested Capital was 0.75% for Q4 2025 at Enanta Pharmaceuticals, up from 1.16% in the prior quarter.
  • Across five years, Return on Invested Capital topped out at 0.17% in Q1 2021 and bottomed at 1.16% in Q3 2025.
  • Average Return on Invested Capital over 5 years is 0.62%, with a median of 0.57% recorded in 2023.
  • Peak annual rise in Return on Invested Capital hit 15bps in 2025, while the deepest fall reached -35bps in 2025.
  • Year by year, Return on Invested Capital stood at 0.41% in 2021, then increased by 3bps to 0.4% in 2022, then crashed by -76bps to 0.69% in 2023, then tumbled by -30bps to 0.9% in 2024, then rose by 17bps to 0.75% in 2025.
  • Business Quant data shows Return on Invested Capital for ENTA at 0.75% in Q4 2025, 1.16% in Q3 2025, and 1.09% in Q2 2025.